Literature DB >> 26297664

Visualization and quantification of simian immunodeficiency virus-infected cells using non-invasive molecular imaging.

Jiasheng Song1, Zhengxin Cai1, Alexander G White1, Tao Jin1, Xiaolei Wang1, Deepak Kadayakkara2, Carolyn J Anderson1, Zandrea Ambrose3, Won-Bin Young1.   

Abstract

In vivo imaging can provide real-time information and three-dimensional (3D) non-invasive images of deep tissues and organs, including the brain, whilst allowing longitudinal observation of the same animals, thus eliminating potential variation between subjects. Current in vivo imaging technologies, such as magnetic resonance imaging (MRI), positron emission tomography-computed tomography (PET-CT) and bioluminescence imaging (BLI), can be used to pinpoint the spatial location of target cells, which is urgently needed for revealing human immunodeficiency virus (HIV) dissemination in real-time and HIV-1 reservoirs during suppressive antiretroviral therapy (ART). To demonstrate that in vivo imaging can be used to visualize and quantify simian immunodeficiency virus (SIV)-transduced cells, we genetically engineered SIV to carry different imaging reporters. Based on the expression of the reporter genes, we could visualize and quantify the SIV-transduced cells via vesicular stomatitis virus glycoprotein pseudotyping in a mouse model using BLI, PET-CT or MRI. We also engineered a chimeric EcoSIV for in vivo infection study. Our results demonstrated that BLI is sensitive enough to detect as few as five single cells transduced with virus, whilst PET-CT can provide 3D images of the spatial location of as few as 10 000 SIV-infected cells. We also demonstrated that MRI can provide images with high spatial resolution in a 3D anatomical context to distinguish a small population of SIV-transduced cells. The in vivo imaging platform described here can potentially serve as a powerful tool to visualize lentiviral infection, including when and where viraemia rebounds, and how reservoirs are formed and maintained during latency or suppressive ART.

Entities:  

Mesh:

Year:  2015        PMID: 26297664      PMCID: PMC4857449          DOI: 10.1099/jgv.0.000245

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  7 in total

1.  Whole body MRI of the non-human primate using a clinical 3T scanner: initial experiences.

Authors:  Chun-Xia Li; Xiaodong Zhang
Journal:  Quant Imaging Med Surg       Date:  2017-04

2.  Harnessing Novel Imaging Approaches to Guide HIV Prevention and Cure Discoveries-A National Institutes of Health and Global HIV Vaccine Enterprise 2017 Meeting Report.

Authors:  Brigitte E Sanders-Beer; Yegor Voronin; David McDonald; Anjali Singh
Journal:  AIDS Res Hum Retroviruses       Date:  2018-01-05       Impact factor: 2.205

3.  In Vivo Excision of HIV-1 Provirus by saCas9 and Multiplex Single-Guide RNAs in Animal Models.

Authors:  Chaoran Yin; Ting Zhang; Xiying Qu; Yonggang Zhang; Raj Putatunda; Xiao Xiao; Fang Li; Weidong Xiao; Huaqing Zhao; Shen Dai; Xuebin Qin; Xianming Mo; Won-Bin Young; Kamel Khalili; Wenhui Hu
Journal:  Mol Ther       Date:  2017-03-30       Impact factor: 11.454

Review 4.  Tools for Visualizing HIV in Cure Research.

Authors:  Julia Niessl; Amy E Baxter; Daniel E Kaufmann
Journal:  Curr HIV/AIDS Rep       Date:  2018-02       Impact factor: 5.071

5.  Functional screening of guide RNAs targeting the regulatory and structural HIV-1 viral genome for a cure of AIDS.

Authors:  Chaoran Yin; Ting Zhang; Fang Li; Fan Yang; Raj Putatunda; Won-Bin Young; Kamel Khalili; Wenhui Hu; Yonggang Zhang
Journal:  AIDS       Date:  2016-05-15       Impact factor: 4.177

Review 6.  Highlights of the Latest Developments in Radiopharmaceuticals for Infection Imaging and Future Perspectives.

Authors:  Ekaterina Dadachova; Drauzio E N Rangel
Journal:  Front Med (Lausanne)       Date:  2022-02-11

Review 7.  Visualizing the Immune System: Providing Key Insights into HIV/SIV Infections.

Authors:  Jacob D Estes; Roger LeGrand; Constantinos Petrovas
Journal:  Front Immunol       Date:  2018-03-02       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.